"UK Gill Heart & Vascular Institute is nationally recognized as a leader in advancing the treatment and prevention of cardiovascular disease."

During the past decade, University of Kentucky Gill Heart Institute conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 5 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Kentucky Gill Heart Institute" #1 sponsor was "Abbott Medical Devices" with 1 trials, followed by "Biotronik, Inc." with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored, "Juventas Therapeutics, Inc." with 1 trials sponsored and "Lisata Therapeutics, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Kentucky Gill Heart Institute" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "EKOS Corporation" with 1 trials as a collaborator and "Zoll Medical Corporation" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "University of Kentucky Gill Heart Institute" are "Atrial Fibrillation" (2 trials), "Acute Pulmonary Embolism" (1 trials), "Cardiac Resynchronization Therapy" (1 trials), "Coronary Artery Disease (CAD)" (1 trials) and "Coronary Artery Lesions" (1 trials). Many other conditions were trialed in "University of Kentucky Gill Heart Institute" in a lesser frequency.

Most popular intervention types in "University of Kentucky Gill Heart Institute" are "Device" (4 trials), "Drug" (4 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Apixaban" (1 trials), "CRT-DX" (1 trials), "DAPT" (1 trials), "EKOS EkoSonic Endovascular System" (1 trials) and "M118" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Kentucky Gill Heart Institute" are 8 trials for "All" genders.

Currently, there are NaN active trials in "University of Kentucky Gill Heart Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in University of Kentucky Gill Heart Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in University of Kentucky Gill Heart Institute, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".